|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Subramaniam S, Thakur RK, Yadav VK, Nanda
R, Chowdhury S and Agrawal A: Lung cancer biomarkers: State of the
art. J Carcinog. 12:32013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rhim AD, Mirek ET, Aiello NM, Maitra A,
Bailey JM, McAllister F, Reichert M, Beatty GL, Rustgi AK,
Vonderheide RH, et al: EMT and dissemination precede pancreatic
tumor formation. Cell. 148:349–361. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Haeno H, Gonen M, Davis MB, Herman JM,
Iacobuzio-Donahue CA and Michor F: Computational modeling of
pancreatic cancer reveals kinetics of metastasis suggesting optimum
treatment strategies. Cell. 148:362–375. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Verdecchia A, Francisci S, Brenner H,
Gatta G, Micheli A, Mangone L and Kunkler I; EUROCARE-4 Working
Group, : Recent cancer survival in Europe: A 2000-02 period
analysis of EUROCARE-4 data. Lancet Oncol. 8:784–796. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yilmaz M and Christofori G: Mechanisms of
motility in metastasizing cells. Mol Cancer Res. 8:629–642. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hornstein I, Pikarsky E, Groysman M, Amir
G, Peylan-Ramu N and Katzav S: The haematopoietic specific signal
transducer Vav1 is expressed in a subset of human neuroblastomas. J
Pathol. 199:526–533. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wakahashi S, Sudo T, Oka N, Ueno S,
Yamaguchi S, Fujiwara K, Ohbayashi C and Nishimura R: Vav1
represses E-cadherin expression through the transactivation of
Snail and Slug: A potential mechanism for aberrant epithelial to
mesenchymal transition in human epithelial ovarian cancer. Transl
Res. 162:181–190. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Grassilli S, Brugnoli F, Lattanzio R,
Rossi C, Perracchio L, Mottolese M, Marchisio M, Palomba M, Nika E,
Natali PG, et al: High nuclear level of Vav1 is positive prognostic
factor in early invasive breast tumors: A role in modulating genes
related to the efficiency of metastatic process. Oncotarget.
5:4320–4336. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fernandez-Zapico ME, Gonzalez-Paz NC,
Weiss E, Savoy DN, Molina JR, Fonseca R, Smyrk TC, Chari ST,
Urrutia R and Billadeau DD: Ectopic expression of VAV1 reveals an
unexpected role in pancreatic cancer tumorigenesis. Cancer Cell.
7:39–49. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bartolomé RA, Molina-Ortiz I, Samaniego R,
Sánchez-Mateos P, Bustelo XR and Teixidó J: Activation of Vav/Rho
GTPase signaling by CXCL12 controls membrane-type matrix
metalloproteinase-dependent melanoma cell invasion. Cancer Res.
66:248–258. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lazer G, Idelchuk Y, Schapira V, Pikarsky
E and Katzav S: The haematopoietic specific signal transducer Vav1
is aberrantly expressed in lung cancer and plays a role in
tumourigenesis. J Pathol. 219:25–34. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu Y, Wang Y, Zhang Y, Miao Y, Zhao Y,
Zhang PX, Jiang GY, Zhang JY, Han Y, Lin XY, et al: Abnormal
expression of p120-catenin, E-cadherin, and small GTPases is
significantly associated with malignant phenotype of human lung
cancer. Lung Cancer. 63:375–382. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ye H, Zhang Y, Geng L and Li Z: Cdc42
expression in cervical cancer and its effect on cervical tumor
invasion and migration. Int J Oncol. 46:757–763. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kamai T, Yamanishi T, Shirataki H, Takagi
K, Asami H, Ito Y and Yoshida K: Over-expression of RhoA, Rac1, and
Cdc42 GTPases is associated with progression in testicular cancer.
Clin Cancer Res. 10:4799–4805. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kikuchi K, Li X, Zheng Y and Takano Y:
Invasion of breast cancer cells into collage matrix requires TGF-α
and Cdc42 signaling. FEBS Lett. 585:286–290. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Razidlo GL, Schroeder B, Chen J, Billadeau
DD and McNiven MA: Vav1 as a central regulator of invadopodia
assembly. Curr Biol. 24:86–93. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yao R, Wang Y, Lubet RA and You M:
Differentially expressed genes associated with mouse lung tumor
progression. Oncogene. 21:5814–5821. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Du DS, Yang XZ, Wang Q, Dai WJ, Kuai WX,
Liu YL, Chu D and Tang XJ: Effects of CDC42 on the proliferation
and invasion of gastric cancer cells. Mol Med Rep. 13:550–554.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zarogoulidis K, Zarogoulidis P, Darwiche
K, Boutsikou E, Machairiotis N, Tsakiridis K, Katsikogiannis N,
Kougioumtzi I, Karapantzos I, Huang H and Spyratos D: Treatment of
non-small cell lung cancer (NSCLC). J Thorac Dis. 5 Suppl
4:S389–S396. 2013.PubMed/NCBI
|
|
21
|
Ma L, Wang B, Long Y and Li H: Effect of
traditional Chinese medicine combined with Western therapy on
primary hepatic carcinoma: A systematic review with meta-analysis.
Front Med. 11:191–202. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen QY, Jiao DM, Yao QH, Yan J, Song J,
Chen FY, Lu GH and Zhou JY: Expression analysis of Cdc42 in lung
cancer and modulation of its expression by curcumin in lung cancer
cell lines. Int J Oncol. 40:1561–1568. 2012.PubMed/NCBI
|
|
23
|
Refaat A, Abdelhamed S, Yagita H, Inoue H,
Yokoyama S, Hayakawa Y and Saiki I: Berberine enhances tumor
necrosis factor-related apoptosis-inducing ligand-mediated
apoptosis in breast cancer. Oncol Lett. 6:840–844. 2013.PubMed/NCBI
|
|
24
|
Ma L, Wang R, Nan Y, Li W, Wang Q and Jin
F: Phloretin exhibits an anticancer effect and enhances the
anticancer ability of cisplatin on non-small cell lung cancer cell
lines by regulating expression of apoptotic pathways and matrix
metalloproteinases. Int J Oncol. 48:843–853. 2016.PubMed/NCBI
|
|
25
|
Li L: The effect of Corydalis saxicola
Bunting on anti-inflammation. Chin J Ethnomed Ethnopharm. 18:20–21.
2009.(In Chinese).
|
|
26
|
Xie PS, Li AY, Zhou F and Zhao Y: The
experimental screening of Chinese herbal medicine in anti-cancer
effect. ShiZhen Chin Med. 19–20. 1996.(In Chinese).
|
|
27
|
Dong K, Wu LZ and Liang YY: The role of
Corydalis saxicola alkaloids in mice immunity. Chin J Immunol.
238–241. 1995.(In Chinese).
|
|
28
|
Xiong LY and Li LL: The clinical trials of
Octreotide combined Corydalis saxicola Bunting injection to treat
advanced liver cancer. Sichuan Journal of Cancer Control. 232–234.
2005.(In Chinese).
|
|
29
|
Wu CF, Liu W, Li FL and Xu YM: The effect
of Corydalis Saxicola bunting total alkaloids (CABTA) on monoamine
neurotransmitters in rat brain. J Shenyang Pharm Univ. 101–104.
1994.(In Chinese).
|
|
30
|
Yin JK and Liao JX: The role of Corydalis
Saxicola bunting total alkaloids on Tca8113 cells proliferation and
apoptosis. Chin J of Oral and Maxillofacial Surg. 4:245–248.
2010.(In Chinese).
|
|
31
|
Tang CL, Zheng H, Wang J, Song H, Lu SY,
Cheng B, Wu F, Zhang HY, Ruan JX, Liang YH and Su ZH: The active
component identification of herba Corydalis saxicolae extract base
on the quantitative composition-activity relationship in inhibition
of human liver cancer cells SMMC-7721. ShiZhen Chin Med.
27:2372–2375. 2016.(In Chinese).
|
|
32
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hong L, Kenney SR, Phillips GK, Simpson D,
Schroeder CE, Nöth J, Romero E, Swanson S, Waller A, Strouse JJ, et
al: Characterization of a Cdc42 protein inhibitor and its use as a
molecular probe. J Biol Chem. 288:8531–8543. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jin Hua, LI Ji, Ying Wang and Rong Zeng
Jing: Total alkaloids of Corydalis saxicola bunting on A549 lung
cancer cells proliferation, apoptosis and its effect on Caspase,
Survivin expression. Chin J Exp Formulas Chin Med Med Exp Formulas
Chin Med. 9:165–169. 2015.(In Chinese).
|
|
35
|
Ellenbroek SI and Collard JG: Rho GTPases:
Functions and association with cancer. Clin Exp Metastasis.
24:657–672. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Vega FM and Ridley AJ: Rho GTPases in
cancer cell biology. FEBS Lett. 582:2093–2101. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Razidlo GL, Magnine C, Sletten AC, Hurley
RM, Almada LL, Fernandez-Zapico ME, Ji B and McNiven MA: Targeting
pancreatic cancer metastasis by inhibition of Vav1, a driver of
tumor cell invasion. Cancer Res. 75:2907–2915. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Borkham-Kamphorst E, Alexi P, Tihaa L,
Haas U and Weiskirchen R: Platelet-derived growth factor-D
modulates extracellular matrix homeostasis and remodeling through
TIMP-1 induction and attenuation of MMP-2 and MMP-9 gelatinase
activities. Biochem Biophys Res Commun. 457:307–313. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Davis ME, Gumucio JP, Sugg KB, Bedi A and
Mendias CL: MMP inhibition as a potential method to augment the
healing of skeletal muscle and tendon extracellular matrix. J Appl
Physiol (1985). 115:884–891. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang R, Ke ZF, Wang F, Zhang WH, Wang YF,
Li SH and Wang LT: GOLPH3 overexpression is closely correlated with
poor prognosis in human non-small cell lung cancer and mediates its
metastasis through upregulating MMP-2 and MMP-9. Cell Physiol
Biochem. 35:969–982. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Xu X, Chen L, Xu B, Xie Q, Sun M, Deng X,
Wu C and Jiang J: Increased MT2-MMP expression in gastric cancer
patients is associated with poor prognosis. Int J Clin Exp Pathol.
8:1985–1990. 2015.PubMed/NCBI
|
|
42
|
El-Badrawy MK, Yousef AM, Shaalan D and
Elsamanoudy AZ: Matrix metalloproteinase-9 expression in lung
cancer patients and its relation to serum MMP-9 activity,
pathologic type, and prognosis. J Bronchology Interv Pulmonol.
21:327–334. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Buccione R, Caldieri G and Ayala I:
Invadopodia: Specialized tumor cell structures for the focal
degradation of the extracellular matrix. Cancer Metastasis Rev.
28:137–149. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Yamaguchi H, Lorenz M, Kempiak S,
Sarmiento C, Coniglio S, Symons M, Segall J, Eddy R, Miki H,
Takenawa T and Condeelis J: Molecular mechanisms of invadopodium
formation: The role of the N-WASP-Arp2/3 complex pathway and
cofilin. J Cell Biol. 168:441–452. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Poincloux R, Lizárraga F and Chavrier P:
Matrix invasion by tumour cells: A focus on MT1-MMP trafficking to
invadopodia. J Cell Sci. 122:3015–3024. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Sebban S, Farago M, Gashai D, Ilan L,
Pikarsky E, Ben-Porath I and Katzav S: Vav1 fine tunes p53 control
of apoptosis versus proliferation in breast cancer. PLoS One.
8:e543212013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Grassilli S, Brugnoli F, Lattanzio R,
Rossi C, Perracchio L, Mottolese M, Marchisio M, Palomba M, Nika E,
Natali PG, et al: High nuclear level of Vav1 is a positive
prognostic factor in early invasive breast tumors: A role in
modulating genes related to the efficiency of metastatic process.
Oncotarget. 5:4320–4336. 2014. View Article : Google Scholar : PubMed/NCBI
|
